Skip to main content

Table 3 Characteristics of 36 adult patients with tigecycline non-susecptible K. pneumoniae bacteremia

From: Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniaebacteremia in Taiwan

Characteristic n (%)
Age (years, median, IQR) 75.5, 63.5–81.7
Male sex 27 (75)
Underlying disease  
 Immunosuppressiona 9 (25)
 Diabetes mellitus 18 (50)
 Chronic obstructive lung disease 5 (13.9)
 Cerebral vascular disease 10 (27.8)
 Chronic kidney disease, stage = 4 or 5 13 (36.1)
  Hemodialysis 11 (30.6)
 Malignancy 14 (38.9)
  Hematological malignancy 3 ( 8.3)
  Solid tumor 11 (30.6)
 Liver cirrhosis 3 (8.3)
Charlson comorbidity score (median, IQR) 3, 2–6
Community-acquired infections 3 ( 8.3)
Healthcare-associated infectionsb 6 (16.7)
Nosocomial infectionsb 27 (75)
 ICU 14 (38.9)
 Medical ward 8 (22.2)
 Surgical ward 5 (13.9)
Polymicrobial infection 2 (5.6)
Antibiotic exposure in the past 30 days, ≥3 days  
 Any 29 (80.6)
 Tigecycline 13 (36.1)
 Glycopeptides 11 (30.6)
 β-lactams plus β-lactamase inhibitors 12 (33.3)
 First- and second-generation cephalosporins 11 (30.6)
 Third- or fourth-generation cephalosporins 10 (27.8)
 Carbapenem 9 (25)
 Fluoroquinolones 8 (22.2)
 Metronidazole 9 (25)
Ward, duration of stay and devices at the time of bacteremia  
 Acquired after ICU >48 h 14 (38.9)
 Days of hospitalization before bacteremia (median, IQR) 48, 18–82
 Urinary catheter 17 (47.2)
 Central venous catheter 23 (63.9)
 Mechanical ventilation 18 (50)
Pitt bacteremia score (mean ± SD) 4 ± 4
APACHE II score (mean ± SD) 23 ± 10
Infection sources and clinical syndrome  
 Pneumonia 10 (27.8)
 Intra-abdominal infection other than biliary-tract infection 5 (13.9)
 Biliary-tract infection 7 (19.4)
 Skin and soft-tissue infection 2 (5.6)
 Catheter infection 1 (2.8)
 Urinary-tract infection 1 (2.8)
 Unknown primary focus 10 (27.8)
Appropriate antibiotic treatment 17 (47.2)
Outcome  
 Presentation with septic shock 19 (52.8)
 Requiring admission to ICU after bacteremia 19 (52.8)
 In-hospital death 17 (47.2)
 28-day mortality 14 (38.9)
  1. IQR, interquartile range; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation; SD, standard deviation.
  2. aImmunosuppression includes patients who underwent solid-organ transplantation, corticosteroid therapy, and immunosuppression therapy.
  3. bBacteremia was defined to be nosocomial-acquired if the index blood culture was collected >48 h after hospital admission and no signs or symptoms of infection were noted at hospital admission. Bacteremia with onset ≤48 h after hospital admission was classified as healthcare-associated infection if patients met any of the following criteria: having received intravenous therapy at home or in an outpatient clinic during the past 30 days; having received renal dialysis in a hospital or clinic during the past 30 days; having hospitalized for 2 or more days during the past 90 days; or having resided in a nursing home or long-term care facility.